SSY Group Gains Approval for New Drug Production

SSY Group ( (HK:2005) ) has provided an announcement.

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two chemical drugs: Calcium Gluconate and Sodium Chloride Injection, and Potassium Chloride Granules. These approvals mark a significant step in the company’s product development, enhancing its portfolio in treating conditions such as acute hypocalcemia and hypokalemia, which could strengthen its market position and offer new opportunities for growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating medical solutions for various health conditions, with a market focus on drug production and registration in compliance with national medical standards.

Average Trading Volume: 9,842,358

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.17B

For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.